Baseline characteristics

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma · Source last updated 2014-09-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      14

   units

   Participants

groups

1. description

   Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) Doxorubicin : 50 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle Prednisone : 100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle Zolinza (vorinostat) : Starting oral dose (Schedule A) of 300 mg once a day on Days 5-14 of 21 day cycle. Cyclophosphamide : 750 mg/m\^2 by vein over 1 hour on Day 1 of 21 day cycle Vincristine : 1.4 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle

   id

   BG000

   title

   Zolinza + CHOP

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            29

            upper Limit

            83

            value

            55

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            6

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            8

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            14

      title

      United States

   param Type

   NUMBER

   title

   Region of Enrollment

   unit Of Measure

   participants

4. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            6

      title

      300 mg once daily on Days 5 to14

   2. categories

      1. measurements

         1. group Id

            BG000

            value

            2

      title

      200 mg twice daily on Days 5 to14

   3. categories

      1. measurements

         1. group Id

            BG000

            value

            6

      title

      300 mg three times daily on Days -2 to 3

   description

   Number of participants who received either Vorinostat treatment Schedule A (300 mg once daily or 200 mg twice daily) for Phase I or Schedule B (300 mg three times daily) for Phase II.

   param Type

   NUMBER

   title

   Vorinostat Treatment (Schedule A/Schedule B)

   unit Of Measure

   participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice